Atacand Approved for Chronic Heart Failure Treatment

Published: 2004-12-03 06:57:00

Updated: 2004-12-03 06:57:00

AstraZeneca’s Atacand (candesarten cilexetil), an Angiotensin II Receptor Blocker (ARB) for the treatment of hypertension, has been additionally approved for the treatment of Chronic Heart Failures (CHF) by passing the European Mutual Recognition Procedure. This indicates that Atacand is now app...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK